Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2025/2026 influenza season

as of November 11, 2026

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	0	1 (0.5%)	1 (0.5%)	0	0	112 (100%)	12 (1.0%)	0	0	0	0	341 (100%)	0	0	0	0	0
Number of viruses tested	177	221	221	101	101	112	1,250	336	336	336	336	341	560	245	245	245	245
Number of viruses reported	428						5,646						4,012				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.